Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kith Pradhan

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
The Journal of Clinical Investigation|February 1, 2019
Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinomaNiraj Shenoy, Tushar D Bhagat, John Cheville, et al.
The Journal of Clinical Investigation|May 27, 2025
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromesSrinivas Aluri, Te Ling, Ellen Fraint, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Cancer Discovery|April 5, 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in HematopoiesisJong Jin Jeong, Xiaorong Gu, Ji Nie, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
The Journal of Clinical Investigation|February 20, 2024
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Orsi Giricz, David T Melnekoff, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Cell Reports|December 13, 2025
Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolismBryan Harris, Dinesh K Singh, Billy Truong, et al.
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
The Journal of Clinical Investigation|February 1, 2019
Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinomaNiraj Shenoy, Tushar D Bhagat, John Cheville, et al.
The Journal of Clinical Investigation|May 27, 2025
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromesSrinivas Aluri, Te Ling, Ellen Fraint, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Cancer Discovery|April 5, 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in HematopoiesisJong Jin Jeong, Xiaorong Gu, Ji Nie, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
The Journal of Clinical Investigation|February 20, 2024
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Orsi Giricz, David T Melnekoff, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Cell Reports|December 13, 2025
Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolismBryan Harris, Dinesh K Singh, Billy Truong, et al.
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Pageof 9